Exercise in Methamphetamine Use Disorder Upregulation and Neural Function
NCT03709667, Early phase 1, Completed, University of California, Los Angeles
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exercise in Methamphetamine Use Disorder Upregulation and Neural Function | ClinicalTrials.gov |
| NCT number | NCT03709667 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Early phase 1 | ClinicalTrials.gov |
| Enrollment | 113 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of California, Los Angeles | ClinicalTrials.gov |
| Conditions | Methamphetamine Abuse | ClinicalTrials.gov |
| Interventions | EX, CON | ClinicalTrials.gov |
| First posted | 2018-10-17 | ClinicalTrials.gov |
| Last updated | 2024-05-08 | ClinicalTrials.gov |
Registered outcomes 24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Striatal D2/3 Binding Potential (BPND) Upregulation | 8 weeks | Dopamine D2-type receptor binding potential in the striatum measured with positron emission tomography scanning measured at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Sustained attention | 8 weeks | The Continuous Performance Task will be used to assess sustained attention at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The following outcome variables will be assessed: Correct Detection: Number of responses to the target stimulus. Reaction times: Length of time between stimulus presentation and response. Omission errors: Number of target presentations with no response. Commission errors: Number of responses without target stimulus presentation. High omission rates reflect impaired attention, higher correct detections reflect improved attention. | ClinicalTrials.gov |
| Secondary | Working memory | 8 weeks | The Sternberg Spatial Task will be used to assess working memory at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The number of correct responses will be measured, with higher amounts of correct responses reflecting better working memory. | ClinicalTrials.gov |
| Secondary | Declarative memory | 8 weeks | The Rey Auditory Verbal Learning Test will be used to assess declarative memory at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The number of words correctly recalled will be recorded before and after a 20 minute delay, as well as the number of intrusions. The corresponding Z score and percentile of each participant's responses will be calculated. | ClinicalTrials.gov |
| Secondary | Selective attention | 8 weeks | The Stroop Task will be used to assess working memory at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The number of words, colors, and number of color words within a set time will be measured, as well as the number of errors. Larger amounts of errors reflect worse selective attention, whereas higher numbers of words, colors, and number of color words completed reflect better selective attention. | ClinicalTrials.gov |
| Secondary | Inhibitory control - stop signal task | 8 weeks | The Stop-signal task will be used to assess inhibitory control at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Inhibitory control - reversal learning | 8 weeks | A reversal learning task will be used to assess inhibitory control at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Reward-based decision-making | 8 weeks | A monetary delay-discounting task/questionnaires and the Balloon Analogue Risk task will be used to assess reward-based decision-making at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The primary outcome measures include the number of balloon pumps and earnings, with more pumps and earnings reflecting greater risk. | ClinicalTrials.gov |
| Secondary | Resting state functional connectivity | 8 weeks | Striatum resting state functional connectivity will be measured with a functional magnetic resonance imaging scan at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Task-based brain activity (functional magnetic resonance imaging) - balloon analog risk | 8 weeks | Performance on a cognitive task (the Balloon Analog Risk Task) will be assessed during a functional magnetic resonance imaging scan at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Task-based brain activity (functional magnetic resonance imaging - stop signal | 8 weeks | Performance on a cognitive task the (Stop Signal Task), will be assessed during a functional magnetic resonance imaging scan at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Decision making under risk and ambiguity | 8 weeks | A task involving decision making under during differing types of risk and ambiguity will be used to determine decision making under risk and ambiguity at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The Risk and Ambiguity Task measures tolerance for risk under conditions of known risk (alpha) and unknown risk (beta). | ClinicalTrials.gov |
| Secondary | Loss Aversion | 8 weeks | A computer task and written questionnaire assessing loss preferences will be used to assess loss aversion at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. | ClinicalTrials.gov |
| Secondary | Motor Function | 8 weeks | A finger tapping test will be to assess motor function at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment. The number of finger taps in 10 seconds will be recorded three times per hand, and averaged to create the primary outcome measure reflecting motor function. | ClinicalTrials.gov |
| Other | Personality - impulsivity | 8 weeks | Self-report of impulsivity will be measured at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment with the Barratt Impulsiveness Scale (11). The total score will be calculated as measured at both time points as the primary outcome measure. | ClinicalTrials.gov |
| Other | Personality - novelty seeking | Baseline | Self-report of novelty seeking will be measured at baseline prior to the EX or CON intervention using the Temperament and Character Inventory. | ClinicalTrials.gov |
| Other | Personality - reward dependence | Baseline | Self-report of reward dependence will be measured at baseline prior to the EX or CON intervention using the Temperament and Character Inventory. | ClinicalTrials.gov |
| Other | Methamphetamine Craving | 8 weeks | Self-report of craving of methamphetamine will be measured at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment using the Brief Meth Craving Scale. A total summary score is calculated and used as the primary outcome measure. | ClinicalTrials.gov |
| Other | Cocaine Craving | 8 weeks | Self-report of craving of cocaine will be measured at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment using the Cocaine Craving Questionnaire-Brief. A total summary score is calculated and used as the primary outcome measure. | ClinicalTrials.gov |
| Other | Personality- risk taking | 8 weeks | Self-report of risk perceptions and risk behaviors will be measured at baseline prior to exercise (EX) and after 8 weeks of EX (vs. CON) treatment using the Domain Specific Risk Taking Scale. Three scores will be computed: Risk Taking, Risk Perception, and Expected Benefits and changes in these scores will be measured at both time points. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01DA045162 | Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function | LONDON, EDYTHE DANICK; MOONEY, LARISSA JEANETTE | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL INSTITUTE ON DRUG ABUSE | 2018 to 2022 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Balloon Risk | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Delay Discounting | Secondary outcome | ConductCognition |
| Finger Tapping Task | Secondary outcome | ConductCognition |
| Probabilistic Reversal Learning | Secondary outcome | ConductCognition |
| Stop-Signal Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)